While there are no medicines that specifically target ERO1α, this systematic review’s findings should direct future drug development efforts by drawing attention to the significance of ERO1α overexpression in breast cancer and its role in important pathways that promote tumor growth. Here, ERO1A is linked to breast carcinoma.